Showing results (41-50 of 207) with videos related to
Sort By:
Pageof 21
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 23, 2007
Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucomaVasantha P Rao, David L EpsteinKidney International|February 17, 2012
Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigmsLinda Shavit, Meyer D Lifschitz, Murray EpsteinThe American Journal of Medicine|September 20, 2020
The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the FutureJoão Pedro Ferreira, Murray Epstein, Faiez ZannadJournal of Cardiovascular Translational Research|March 30, 2012
Vascular injury in cancer survivorsDaniel A Mulrooney, Anne H Blaes, Daniel DuprezCardio-Oncology (London, England)|April 14, 2023
Effect of insulin resistance on CAC scores in cancer survivorsN Jacobi, S Ortman, L Buda, et al.Chemsuschem|November 19, 2016
Investigation of Methane Oxidation Reactions Over a Dual-Bed Catalyst System using 18 O Labelled DRIFTS couplingMelissandre Richard, Daniel Duprez, Nicolas Bion, et al.The American Journal of Medicine|August 22, 2012
Hypertension and chronic kidney disease progression: why the suboptimal outcomes?Anil K Bidani, Karen A Griffin, Murray EpsteinHypertension (Dallas, Tex. : 1979)|March 27, 2020
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System BlockersA H Jan Danser, Murray Epstein, Daniel BatlleJournal of the American Society of Nephrology : JASN|June 7, 2005
Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?Vito M Campese, Mitra K Nadim, Murray EpsteinAnnals of Internal Medicine|June 3, 2009
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertensionJames R Sowers, Adam Whaley-Connell, Murray EpsteinPageof 21